HTA128 Reassessment of Orphan Drugs After Exceeding the 50 Mio. Euro Revenue Threshold: Effects on Added Benefit and Price Discount
Dec 1, 2022, 00:00 AM
10.1016/j.jval.2022.09.1586
https://www.valueinhealthjournal.com/article/S1098-3015(22)03791-3/fulltext
Section Title :
Section Order :
11138
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)03791-3&doi=10.1016/j.jval.2022.09.1586